EVRYSDIⓇ (risdiplam) has been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) benefit list effective August 7, 2023.
The specific criteria for reimbursement are in line with recommendations made by CADTH in 2021.
Link below to the criteria found in the Newfoundland and Labrador Bulletin No.137
Initiation Criteria
1. Pre-symptomatic patients with two or three copies of the SMN2 gene, OR
2. Had the disease for <6 months, two copies of SMN2, and symptom onset after the first week after birth and on, or before seven months of age; OR 3. Patients under the age of 18 with symptom onset > 6 months of age, and never achieved the ability to walk independently.†
Stopping Criteria
1. For those pre-symptomatic at initiation: no improvement on HINE-2, CHOP INTEND, or HFMSE, OR
2. For those symptomatic at initiation: no improvement in HINE-2, CHOP INTENT, or HFMSE, OR
3. Permanent invasive ventilation required
No information available at this time.